1/18/2013

Astellas Pharma said the FDA has accepted its supplemental new drug application for Tarceva, or erlotinib, as a first-line treatment for EGFR-positive metastatic or locally advanced nonsmall-cell lung cancer. The application was given priority-review designation.

Related Summaries